Autoimmune Disease Diagnostics Market Size - Global Industry, Share, Analysis, Trends and Forecast 2022 - 2030

The Global Autoimmune Disease Diagnostics Market Size accounted for USD 4.4 Billion in 2021 and is projected to occupy a market size of USD 8.2 Billion by 2030 growing at a CAGR of 7.2% from 2022 to 2030.

Autoimmune diseases are body’s unusual immune reaction that produce antibodies which attack own tissues and cells. This usually causes destruction and weakening of healthy tissues. There are almost 80 types of autoimmune diseases existing in the world which includes rheumatoid arthritis or systemic lupus erythematosus. Auto antibody test, complete blood count, antinuclear antibody test, erythrocyte sedimentation rate and C-reactive protein are some of the tests used for diagnosis of the autoimmune disease.

Autoimmune Disease Diagnostics Market Report Statistics

• Global autoimmune disease diagnostics market revenue is projected to reach USD 8.2 Billion by 2030 with a CAGR of 7.2% from 2022 to 2030
• North America autoimmune disease diagnostics market share generated over 35% shares in 2021
• According to Johns Hopkins data, autoimmune disease affects 3% of the US population evaluating around 10 million people
• Asia-Pacific autoimmune disease diagnostics market growth will register CAGR of over 8% from 2022 to 2030
• Based on product, localized recorded over 64% of the overall market share in 2021
• Among end-use, hospitals sector generated shares of over 52% in 2021
• Increasing adoption of biosensors in diagnostic is a popular autoimmune disease diagnostics market trend that fuels the industry demand

Global Autoimmune Disease Diagnostics Market Dynamics

Market Drivers

• Growing prevalence of autoimmune disease
• Favorable government policies for research activities
• Rising awareness regarding autoimmune disorders in emerging nations

Market Restraints

• Requirement of high capital investment
• High rate of false positive results

Market Opportunities

• Rising adoption of lab automation technologies
• Advancement in healthcare technology

Autoimmune Disease Diagnostics Market Report Coverage

Autoimmune Disease Diagnostics Market Growth Factors

Increasing occurrences of diseases, growing demand for better and accurate diagnostic procedures, rising awareness towards the benefits of early diagnosis, various research and development activities, and initiatives taken by favorable governments regulations are some of the key factors that are fueling the autoimmune disease diagnostics market growth across the globe. Rising occurrences of various diseases such as Hashimoto’s thyroiditis, rheumatoid arthritis and various initiatives taken by favorable governments are some of the fundamental factors driving the global autoimmune disease diagnostics market growth. According to the American Autoimmune Related Diseases Association, around 50 million people from the region are presently suffering from autoimmune related disorders. This factor is anticipated to create immense opportunities for the global autoimmune disease diagnostics market over the forecast period. Several initiatives in order to decrease the cost required to cure these diseases is also anticipated to supplement the overalls market growth during the forecast period. Furthermore, rapidly increasing occurrences of various diseases along with the growing awareness amongst the patients is the key factor that positively impacting the growth of the segment.

Development of healthcare infrastructure with the rising expenditure is expected to boost the demand for the various enhanced diagnostic methods for better treatment. The growing demand for improved and accurate diagnostic procedures due to the growth in prevalence of the various diseases is projected to boost the adoption of autoimmune disease diagnostics methods throughout the forecast period. In order to develop superior diagnosis and treatment methods the wide-ranging research and development activities are supported by government. Such research activities are expected to further spur the overall market growth. American Autoimmune Related Diseases Association has also taken the large number of initiatives in order to increase the awareness towards the advantages of early diagnosis. However, lack of skilled professionals in healthcare industry and complex and long process for diagnosis of autoimmune disease are some of the major factors that may hamper the growth of the autoimmune disease diagnostics market globally.

Autoimmune Disease Diagnostics Market Segmentation

The global autoimmune disease diagnostics market is segmented based on product, test type, end-use, and geography.

Autoimmune Disease Diagnostics Market By Product

• Systemic
  • Rheumatoid Arthritis
  • Systemic Lupus Erythematosus (SLE)
  • Psoriasis
  • Multiple Sclerosis
  • Others
• Localized
  • Inflammatory Bowel Disease
  • Type 1 Diabetes
  • Thyroid
  • Others

According to the autoimmune disease diagnostics industry analysis, localized sub-segment occupied significant market share in 2021 and will endure its dominance in the coming years. However, the systemic sub-segment is anticipated to attain fastest growth rate during the forecast timeframe from 2022 to 2030. This significant market share is related to the rapidly rising incidence of systemic autoimmune diseases, which are linked to rising morbidity and mortality rates.

Autoimmune Disease Diagnostics Market By Test Type

• Antinuclear Antibody Tests
• Autoantibody Tests
• C-reactive Protein (CRP)
• Complete Blood Count (CBC)
• Urinalysis
• Others

Based on test type, the antinuclear antibody tests sub-segment gathered maximum amount of shares in 2021 and is anticipated to witness a substantial growth rate in the forecast period. The high prevalence of immune system-damaging conditions like type 1 diabetes, myasthenia gravis, Addison's disease, rheumatoid arthritis, etc. is largely responsible for this market's dominating growth. Additionally, autoantibody tests also occupied considerable market share during the same time period.

Autoimmune Disease Diagnostics Market By End-Use

• Hospitals
• Diagnostics Centers
• Others

According to the autoimmune disease diagnostics market forecast, the hospitals sub-segment is expected to occupy a notable market share during 2022 to 2030. The hospitals' increased use of challenging interventional procedures and autoimmune disease diagnostic methods is the cause of this significant market share. Furthermore, a few diagnostic companies have recently formed strategic alliances with hospitals. This trend is predicted to continue in the coming years in order to meet the massive number of patient needs across various regions.

Autoimmune Disease Diagnostics Market Regional Outlook

North America

• U.S.
• Canada

Europe

• U.K.
• Germany
• France
• Spain
• Rest of Europe

Asia-Pacific

• India
• Japan
• China
• Australia
• South Korea
• Rest of Asia-Pacific

Latin America

• Brazil
• Mexico
• Rest of Latin America

The Middle East & Africa

• South Africa
• GCC Countries
• Rest of the Middle East & Africa (ME&A)

Autoimmune Disease Diagnostics Market Regional Analysis

The European autoimmune disease diagnostics industry is likely to be the second-largest in the world. The growing healthcare sector, rising laboratory automation, and aggressive market-growth strategies used by key regional competitors are all factors in this region. In terms of growth, the Asia-Pacific region is likely to attain an impressive growth rate (CAGR) during the course of the forecasted years from 2022 to 2030. The Asia-Pacific region has gotten better its healthcare scenario by introducing novel diagnostic products, which are expected to increase the introduction of these diagnostic tests across the continent, propelling it to the top of the Autoimmune Disease Diagnostics Market.

Autoimmune Disease Diagnostics Market Players

The global autoimmune disease diagnostics market is characterized by the presence of experienced and established players. Some of the key players include Abbott Laboratories, AstraZeneca, Beckman Coulter Inc., Bio-Rad Laboratories Inc., F. Hoffmann-La Roche, Hemagen Diagnostics Inc., Inova Diagnostics Inc., Novartis AG, Pfizer Inc., and Sanofi-aventis.